Journal of Multiple Sclerosis
ISSN - 2376-0389NLM - 101654564
Silvia Messina
Italy
Research Article
Cyclophosphamide Pulses Therapy after Natalizumab Discontinuation for Multiple Sclerosis: A Multicentre Study
Author(s): Marco Capobianco, Marianna Lo Re, Francesca Sangalli, Lucia Moiola, Paola Perini, Paolo Gallo, Maura Danni, Leandro Provinciali, Annamaria Repice, Luca Massacesi, Silvia Messina, Francesco Patti, Alice Laroni, Gian Luigi Mancardi, Eugenio Pucci, Massimiliano Calabrese and Antonio BertolottoMarco Capobianco, Marianna Lo Re, Francesca Sangalli, Lucia Moiola, Paola Perini, Paolo Gallo, Maura Danni, Leandro Provinciali, Annamaria Repice, Luca Massacesi, Silvia Messina, Francesco Patti, Alice Laroni, Gian Luigi Mancardi, Eugenio Pucci, Massimiliano Calabrese and Antonio Bertolotto
Importance: Natalizumab discontinuation induces the recurrence of Multiple Sclerosis (MS) disease activity: Currently no therapeutic approach has been found able to abolish disease reactivation.
Objective: To collect data from patients with MS switching from natalizumab to cyclophosphamide.
Design: Retrospective multicentre study.
Setting: Nine Multiple Sclerosis Centers in Italy.
Participants: A total of 47 patients with clinically definite RR-MS switched to cyclophosphamide after natalizumab discontinuation. Two patients were excluded from the analysis because received less than 12 natalizumab infusions. The remaining 45 patients were subdivided into two main groups: Early Treatment (period of washout between natalizumab and cyclophosphamide 1 to 3 months), La.. View More»
